HOME >> BIOLOGY >> NEWS
Novel pathway identifies rapamycin as tumor angiogenesis inhibitor

New research has uncovered a signaling pathway sufficient to induce formation of abnormal tumor-like blood vessels in otherwise healthy, normal tissues. These changes in vasculature were reversible and could be blocked by rapamycin, a compound that is currently in clinical use as an immunosuppressant and under investigation as an anticancer therapy. The findings appear in the August issue of Cancer Cell, published by Cell Press.

Compared to normal blood vessels, blood vessels associated with tumors are large, twisted, and leaky. Previous research has shown that overexpression of the cytokine VEGF-A leads to formation of tumor-like blood vessels. Dr. Laura E. Benjamin, from Beth Israel Deaconess Medical School and Harvard Medical School, and colleagues observed that tumor blood vessel cells exhibit activation of a signaling molecule, called Akt, that acts downstream of VEGF-A and has been linked to blood vessel cell survival. To investigate the function of Akt, the researchers used transgenic mice that expressed activated Akt in normal endothelial cells without the complicating influence of tumor cells.

Activation of Akt stimulated formation of abnormal blood vessels in healthy, normal tissues. The Akt-induced vessels had the same structural and functional abnormalities seen in tumor blood vessels. Simply removing or inhibiting the activated Akt was sufficient to reverse the vascular changes. Treatment with rapamycin, a compound with antiproliferative and immunosuppressive properties known to decrease Akt activation, blocked Akt-driven changes in blood vessels. Rapamycin also reduced tumor growth and abnormal vasculature in a mouse tumor model.

"Rapamycin inhibited tumor growth and tumor vascular permeability, which we hypothesize are in part due to effects of rapamycin on endothelial Akt activation. These findings indicate a possible clinical utility of rapamycin as an angiogenesis inhibitor and support a novel pathway for rapamycin
'"/>

Contact: Heidi Hardman
hhardman@cell.com
617-397-2879
Cell Press
14-Aug-2006


Page: 1 2

Related biology news :

1. Novel sugar-to-hydrogen technology promises transportation fuel independence
2. Novel system developed to turn data into real-time, interactive 3-D images
3. Novel strategies for healthy aging
4. Novel salamander robot crawls its way up the evolutionary ladder
5. Novel test identifies lymphoma patients likely to respond to new therapy
6. Novel laboratory technique nudges genes into activity
7. Novel approaches to tackling obesity, cancer and MRSA
8. Novel approach to cancer drug given major boost
9. Novel regulation of the common tumor suppressor PTEN
10. Novel EGFR ectodomain mutations in glioblastoma
11. Novel regulatory mechanism identified for key tumor suppressor p53

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/28/2020)... ... 2020 , ... Today bioinformatics leader hc1® announced ... lab testing insights and hc1’s exclusive Local Risk Index in a unified CV19 ... employees returning to the workplace. , “Some of the best ways to keep ...
(Date:5/25/2020)... Kingdom (PRWEB) , ... May 22, 2020 , ... Oxford ... for the detection of SARS-CoV-2, the virus that causes COVID-19. , The ... on-demand analysis of smaller sample numbers, to very large numbers of samples. Hardware ...
(Date:5/21/2020)... (PRWEB) , ... May 20, 2020 , ... Law Enforcement ... remove danger for all of us. The positions of these men and women put ... the defense for not following rules precisely. Officers have always had to face very ...
Breaking Biology News(10 mins):
(Date:7/7/2020)... ... July 06, 2020 , ... Bio-IT World has announced the ... Squibb, the University of Chicago, Massachusetts General Hospital, Mission: Cure, and the Pistoia ... program, highlighting outstanding examples of how technology innovations and strategic initiatives can be ...
(Date:6/28/2020)... ... June 25, 2020 , ... The Indoor Lab, a leading provider of ... businesses of all types to ensure cleanliness, distancing and occupancy with its patent pending ... Space™ enabled business will provide a health performance index system that scores all aspects ...
(Date:6/23/2020)... ... 23, 2020 , ... Kerafast Inc. , developers of ... the availability of the Delta-G-VSV Pseudotyping System for coronavirus research applications. The system, ... SARS-CoV-2 viral entry and COVID-19 vaccine effectiveness at just biosafety level 2 (BSL-2) ...
(Date:6/23/2020)... ... June 23, 2020 , ... Nobilis ... announced that it has filed an Investigational New Drug application (IND) with the ... of its lead drug candidate NBTX-001 in patients with panic disorder (PD). , ...
Breaking Biology Technology:
Cached News: